Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting-Reference-Cited by-同舟云学术

Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting

Published:2019-12 Issue:6 Volume:71 Page:1076-1085
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Dhiman Radha K.,Grover Gagandeep S.,Premkumar Madhumita,Taneja Sunil,Duseja Ajay,Arora Sanjeev,Rathi Sahaj,Satsangi Sandeep,Roy Akash

Funder

Mukh-Mantri Punjab Hepatitis C Relief Fund

Publisher

Elsevier BV

Subject

Hepatology

Reference35 articles.

1. Tackling the hepatitis C disease burden in Punjab, India;Dhiman;J Clin Exp Hepatol,2016

2. The burden of hepatitis C virus infection in Punjab, India: a population-based serosurvey;Sood;PLoS ONE,2018

3. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome;Alter;Semin Liver Dis,2000

4. Consensus statement of HCV task force of the Indian national association for study of the liver (INASL). Part I: status report of HCV infection in India;Puri;J Clin Exp Hepatol,2014

5. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India;Aggarwal;PLoS ONE,2017

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recompensation of Chronic Hepatitis C–Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program;Gastroenterology;2024-08

2. Viral Hepatitis C: From Unraveling the Nature of Disease to Cure and Global Elimination;Digestive Diseases;2024-05-08

3. Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges;Pharmaceutical Medicine;2024-03

4. Utilization, reimbursement, and price trends for Hepatitis C virus medications in the US Medicaid programs: 2001–2021;Exploratory Research in Clinical and Social Pharmacy;2023-12

5. Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs;Journal of Clinical and Experimental Hepatology;2023-09